Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study

Abstract Background: The optimal treatment for bloodstream infections (BSIs) with vancomycin-resistant enterococci (VRE) is unknown. Objective: This study examined outcomes in patients treated with daptomycin or linezolid for VRE BSI. Methods: A retrospective, multicenter, cohort study was performed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2010-09, Vol.32 (10), p.1713-1719
Hauptverfasser:	Crank, Christopher W., PharmD, Scheetz, Marc H., PharmD, Brielmaier, Benjamin, PharmD, Rose, Warren E., PharmD, Patel, Gourang P., PharmD, Ritchie, David J., PharmD, Segreti, John, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetamides - administration & dosage Acetamides - therapeutic use Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use bacteremia Bacteremia - drug therapy Bacteremia - microbiology Bacterial diseases Bacterial sepsis Biological and medical sciences Cohort Studies daptomycin Daptomycin - administration & dosage Daptomycin - therapeutic use Data Interpretation, Statistical Enterococcus - drug effects Enterococcus - isolation & purification Gram-Positive Bacterial Infections - drug therapy Gram-Positive Bacterial Infections - microbiology Gram-Positive Bacterial Infections - mortality Human bacterial diseases Humans Infectious diseases Internal Medicine Linezolid Medical Education Medical sciences Multivariate Analysis outcomes Oxazolidinones - administration & dosage Oxazolidinones - therapeutic use Pharmacology. Drug treatments Prognosis resistance Retrospective Studies Treatment Outcome Vancomycin Resistance - drug effects vancomycin-resistant enterococcus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background: The optimal treatment for bloodstream infections (BSIs) with vancomycin-resistant enterococci (VRE) is unknown. Objective: This study examined outcomes in patients treated with daptomycin or linezolid for VRE BSI. Methods: A retrospective, multicenter, cohort study was performed via chart review. Hospitalized patients treated for VRE BSI with daptomycin or linezolid from September 1, 2003, to June 30, 2007, were identified via pharmacy and microbiology reports at each institution. Patients aged
ISSN:	0149-2918 1879-114X
DOI:	10.1016/j.clinthera.2010.09.008